Latest filings (excl ownership)
RW
Registration withdrawal request
19 Sep 19
SEC STAFF
SEC staff action: Order
22 Apr 19
SEC STAFF
SEC staff action: Order
22 Apr 19
SEC STAFF
SEC staff action: Order
22 Apr 19
SEC STAFF
SEC staff action: Order
22 Apr 19
15-12G
Securities registration termination
29 Mar 19
8-K
Bankruptcy or Receivership
25 Mar 19
8-K
MabVax Therapeutics and Oncotelic Enter into Merger Discussions
4 Jan 19
S-1
IPO registration
20 Nov 18
8-K
Entry into a Material Definitive Agreement
20 Nov 18
10-Q
2018 Q3
Quarterly report
13 Nov 18
CT ORDER
Confidential treatment order
22 Oct 18
8-K
Regulation FD Disclosure
19 Oct 18
8-K
MabVax Therapeutics Audited Financial Statements Reinstated
16 Oct 18
10-Q
2018 Q2
Quarterly report
15 Oct 18
10-Q
2018 Q1
Quarterly report
15 Oct 18
10-K/A
2017 FY
Annual report (amended)
15 Oct 18
25-NSE
Exchange delisting
27 Sep 18
8-K
Entry into a Material Definitive Agreement
9 Jul 18
8-K
MabVax Therapeutics Receives Nasdaq Delist Determination
5 Jul 18
8-K
MabVax Therapeutics Grants Exclusive Sublicense to Y-mAbs Therapeutics for Patented Neuroblastoma Vaccine
3 Jul 18
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
2 Jul 18
8-K
MabVax Therapeutics Receives Superseding Letter Related to the Late Filing of Form 10-Q
28 Jun 18
8-K
MabVax Therapeutics Receives Nasdaq Notification Due to Late Form 10-Q
24 May 18
8-K/A
Financial Statements and Exhibits
22 May 18
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
21 May 18
D
$860K in equity, sold $830K, 11 investors
15 May 18
NT 10-Q
Notice of late quarterly filing
14 May 18
8-K
MabVax Therapeutics Holdings, Inc. Announces Private Placement Offering
3 May 18
8-K
Regulation FD Disclosure
3 May 18
8-K
MabVax Therapeutics Antibody Program Results Featured in Three Presentations at 2018 American Association for Cancer Research (AACR) Annual Meeting
18 Apr 18
8-K
MabVax Therapeutics Receives Continued Listing Deficiency Notice for Nasdaq’s Minimum Stockholders’ Equity Requirements
13 Apr 18
10-K
2017 FY
Annual report
2 Apr 18
8-K
MabVax Therapeutics Reports 2017 Operational and Financial Results and 2018 Milestones
2 Apr 18
8-K
Regulation FD Disclosure
6 Mar 18
8-K
Regulation FD Disclosure
28 Feb 18
8-K
Departure of Directors or Certain Officers
23 Feb 18
8-K
Amendments to Articles of Incorporation or Bylaws
15 Feb 18
Latest ownership filings
SC 13G/A
Mabvax Therapeutics Holdings, Inc.
9 May 19
SC 13G
Mabvax Therapeutics Holdings, Inc.
6 Aug 18
SC 13D/A
Mabvax Therapeutics Holdings, Inc.
25 Jul 18
4/A
PAUL V MAIER
4 Apr 18
4/A
Kenneth M Cohen
4 Apr 18
4
PAUL V MAIER
3 Apr 18
4
Kenneth M Cohen
3 Apr 18
4
PAUL W MAFFUID
3 Apr 18
4
GREGORY P HANSON
3 Apr 18
4
Thomas C Varvaro
3 Apr 18
4
JOHN DAVID HANSEN
3 Apr 18
SC 13D
Mabvax Therapeutics Holdings, Inc.
2 Mar 18
SC 13D/A
Mabvax Therapeutics Holdings, Inc.
2 Mar 18
4
JEFFREY F EISENBERG
23 Feb 18
4
Paul F Resnick
23 Feb 18
4
Kenneth M Cohen
23 Feb 18
4
PAUL W MAFFUID
23 Feb 18
4
PAUL V MAIER
23 Feb 18
4
GREGORY P HANSON
23 Feb 18
4
Thomas C Varvaro
23 Feb 18
4
JOHN DAVID HANSEN
23 Feb 18
4
Philip O. Livingston
23 Feb 18
SC 13D/A
Mabvax Therapeutics Holdings, Inc.
16 Feb 18
SC 13D
Mabvax Therapeutics Holdings, Inc.
13 Feb 18
SC 13D
Mabvax Therapeutics Holdings, Inc.
12 Feb 18
SC 13G/A
Mabvax Therapeutics Holdings, Inc.
31 Jan 18
4
Thomas C Varvaro
24 Jan 18
4
PAUL V MAIER
24 Jan 18
4
Kenneth M Cohen
24 Jan 18
4
JEFFREY F EISENBERG
24 Jan 18
4
Paul F Resnick
18 Jan 18
4
GREGORY P HANSON
18 Jan 18
4
JOHN DAVID HANSEN
18 Jan 18
4
PAUL W MAFFUID
18 Jan 18
4
Philip O. Livingston
16 Jan 18
4
JOHN DAVID HANSEN
16 Jan 18
4
GREGORY P HANSON
16 Jan 18
4
PAUL W MAFFUID
16 Jan 18
4
Paul F Resnick
16 Jan 18
4
PAUL V MAIER
12 Jan 18